Coalition flags ACCME plans

Share this article:
The Coalition for Healthcare Communication said it doesn't oppose ACCME's proposal to set up an independent entity for disbursal of CME funding – provided that it's not the only game in town and CME providers don't have to pay for it.

In a reply to the accrediting body's call for comments, the Coalition, whose members include medical advertising and communications companies, said it was okay with such a scheme as long as it was “an adjunct to, rather than a replacement for, educational grant support as currently governed by the Standards for Commercial Support,” and that funding not favor one group of providers over another. Such an entity should not rely on fees imposed on providers, the Coalition said.

The Coalition opposes an ACCME plan under consideration that would effectively create a “pharma-friendly faculty free” designation, saying it “would have the practical effect of eliminating a large number of eminent educators from participating in accredited CME activities,” ultimately damaging medicine's capacity to improve patient care. The ACCME has said it is considering a specific designation for programs that do not use teachers or authors “that have acted for a commercial interest in promotional and marketing activities.”
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...